US/UK/Canada

Share

Contacts

  • ODI Pharma AB
    Östermalmstorg 1, 11442 Stockholm
    +46738184422
    http://Odipharma.com
    • Pick a time period -
    Tags ( Active)

    ODI Pharma AB: Updated market and business overview

    ODI Pharma AB (“ODI” or the “Company”) hereby present an updated overview of its market position and the latest trends observed in the cannabis industry, particularly in Europe.Progress in the cooperation with Synoptis Pharma Since August 2023, ODI Pharma's exclusive cooperation with Synoptis Pharma (“Synoptis”), integral to the NEUCA group (“NEUCA”), has made notable progress. This alliance, spanning Poland and 23 other countries in Eastern Europe, has effectively executed several product shipments in recent months. These initial orders highlight the increasing demand and showcase ODI's

    ODI Pharma AB appoints Pareto Securities AB as liquidity provider

    ODI Pharma AB (“ODI Pharma” or the “Company”) has today appointed Pareto Securities as the liquidity guarantor for the Company's shares, which are listed for trading on the Spotlight Stock Market. The purpose of the liquidity guarantee is to improve the liquidity of the stock and to reduce the difference between the buying and selling price. The assignment will begin on 19 January 2024.A liquidity provider is an entity that undertakes to promote the trading of a share by ensuring that there are always buy and sell orders in the order book. Pareto Securities, in its role as liquidity

    Announcement from the Annual General Meeting in ODI Pharma AB (publ)

    This is an unofficial translation of a notice to the Annual General Meeting in ODI Pharma AB (publ), originally drafted in Swedish. In case of any discrepancies between the Swedish original and this translation, the Swedish version shall prevail. Today, the 15[th] of December 2023, ODI Pharma AB (publ) held its Annual General Meeting (“AGM”). A summary of the resolutions follows below. The resolutions were made with the required majority.Adoption of the income statement and balance sheet The AGM resolved to adopt the profit and loss account and balance sheet presented, and the

    ODI Pharma AB announces sale of the skincare brand kandol. for 3.2 msek

    ODI Pharma AB (“ODI” or the “Company”) announces today the sale of the skincare brand kandol. to Niclas Kappelin. The transaction, valued at 3.2 million SEK, includes the transfer of all inventories, production materials, trademarks, and copyrights associated with kandol. In connection with the transaction, CEO Derek Simmross and Chairman of the Board Volker Wiederrich will transfer 2,300,000 and 200,000 shares, off market, respectively to the buyer as part of the transaction.ODI announces that the Company has sold the skincare brand kandol. to the main shareholder Niclas Kappelin for 3.2

    Correction: ODI Pharma AB publishes the annual report for the fiscal year 2022/2023

    The correction refers to the completion of the auditor's remark and ODI Pharma's comment which is now included in the press release. The attached annual report, which includes the auditor's report, is unchanged. The Board of Directors and the Chief Executive Officer of ODI Pharma AB (“ODI Pharma”) hereby publishes the annual report for the fiscal year 2022/2023. The annual report, along with the accompanying auditor’s report, is available as an attached file and on the websites of ODI Pharma (www.odipharma.com) and Spotlight Stock Market (www.spotlightstockmarket.com). A Swedish

    ODI Pharma AB publishes the annual report for the fiscal year 2022/2023

    The Board of Directors and the Chief Executive Officer of ODI Pharma AB (“ODI Pharma”) hereby publishes the annual report for the fiscal year 2022/2023. The annual report, along with the accompanying auditor’s report, is available as an attached file and on the websites of ODI Pharma (www.odipharma.com) and Spotlight Stock Market (www.spotlightstockmarket.com). A Swedish translation of the annual report is also available on www.odipharma.com.For more information on ODI Pharma, please contact: Derek Simmross, CEO, ODI Pharma AB                                                E-mail:

    ODI Pharma AB: Publication of interim report report Q1 2023/2024

    ODI Pharma AB (“ODI” or the “Company”) hereby publishes its interim report for the period July 2023 – September 2023. The report is available as an attached document to this press release and on the Company’s website (www.odipharma.com). Below is a summary of the report.First quarter (2023-07-01 – 2023-09-30) The Group's net sales amounted to SEK 528 206 (28 006). The Group's loss after financial items amounted to SEK -1 442 544 (-1 598 205). Result per share amounted to SEK -0.09 (-0.11).* The solidity as of 2023-09-30 was 15% (90%).** * The Company’s result per share: The

    ODI Pharma AB postpones publication of interim report and annual report until November 24, 2023

    ODI Pharma AB (“ODI” or the “Company”) stated in its year-end report that the interim report for the first quarter of 2023/2024 and the annual report for the fiscal year 2022/2023 would be published on November 23, 2023. Instead, the interim report and the annual report will be published on November 24, 2023, three weeks before the Annual General Meeting on December 15, 2023.For more information, please contact: Derek Simmross, CEO, ODI Pharma AB E-mail: info@odipharma.com

    Notice to Annual General Meeting in ODI Pharma AB (publ)

    The shareholders of ODI Pharma AB (publ), 559223–1392, are hereby invited to attend the Annual General Meeting on Friday, 15th of December 2023, at 10.30 in the office of the company at Östermalmstorg 1, 114 42 Stockholm.Right to participate and registrationShareholders who wish to attend the Annual General Meeting shall · be included in the Euroclear Sweden AB share no later than Thursday the 7[th ]of December 2023, and · sign up to the company no later than Monday the 11[th] of December 2023, by e-mail to info@odipharma.com. The notification should state the full name, personal

    ODI Pharma AB: Publication of year-end report for the fiscal year 2022/2023

    ODI Pharma AB (“ODI” or the “Company”) hereby publishes its year-end report for the period July 2022 – June 2023. The report is available as an attached document to this press release and on the Company’s website (www.odipharma.com). Below is a summary of the report.Fourth quarter (2023-04-01 – 2023-06-30) The Group's net sales amounted to SEK 38 418 (14 233) The Group's loss after financial items amounted to SEK -1 896 506 (-2 378 022) Result per share amounted to SEK -0,12 (-0,16)* Fiscal year (2022-07-01 – 2023-06-30) The Group's net sales amounted to SEK 139 457 (544 151)

    ODI Pharma AB enters into exclusive collaboration with Synoptis Pharma Sp. z o.o.

    ODI Pharma AB (“ODI” or “the Company”) hereby announces that the Company has entered through its Polish subsidiary into a collaboration agreement (“Agreement”) with Synoptis Pharma Sp. Z o.o. (“Synoptis”) under which ODI becomes the exclusive supply partner for medicinal cannabis flos products to Synoptis for a period of 5 plus additional optional 3.5 years covering all Eastern and South Eastern European markets, including Poland, Czech Republic, Ukraine, Croatia etc.Milestone for ODI ODI has secured a prime pharmaceutical company in the Eastern European markets as its collaboration

    ODI Pharma AB receives loan financing of EUR 350,000

    ODI Pharma AB (“ODI” or “the Company”) hereby announces that the Company has secured loan financing of EUR 350,000 from an external international party in order to create flexibility in the operations.Loan financing terms and purpose in summary ODI has, as communicated in January 2023, received approval of the Company’s Marketing Authorization Holder (MAH) application from the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products in Poland to distribute and sell its products on the Polish market. The Company thus has the right to distribute and sell its

    ODI Pharma AB: Publication of interim report report Q3 2022/2023

    ODI Pharma AB (“ODI” or the “Company”) hereby publishes its interim report for the period July 2022 – March 2023. The report is available as an attached document to this press release and on the Company’s website (www.odipharma.com). Below is a summary of the report.Third quarter (2023-01-01 – 2023-03-31) The Group's net sales amounted to SEK 10,801 (71,298) The Group's loss after financial items amounted to SEK -942,440 (-2,344,281) Result per share amounted to SEK -0.06 (-0.15)* Nine months (2022-07-01 – 2023-03-31) The Group’s net sales amounted to SEK 112,083 (529,918)

    ODI Pharma AB: Publication of half-year report 2022/2023

    ODI Pharma AB (“ODI” or the “Company”) hereby publishes its half-year report for the period July – December 2022. The report is available as an attached document to this press release and on the Company’s website (www.odipharma.com). Below is a summary of the report.Second quarter (2022-10-01 – 2022-12-31) The Group's net sales amounted to SEK 73,276 (458,620). The Group's loss after financial items amounted to SEK -1,735,431 (-1,401,502). Result per share amounted to SEK -0.11 (-0.09).* Six months (2022-07-01 – 2022-12-31) The Group’s net sales amounted to SEK 101,282 (458,

    ODI Pharma receives approval from the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products in Poland to distribute and sell its products on the Polish market

    ODI Pharma AB (“ODI” or the “the Company”) announces today that the Company has received approval from the Office for Registration of  Medicinal Products, Medical Devices and Biocidal Products (URPL) in Poland for its Marketing Authorization Holder (MAH) application. The approval means that ODI has the right to distribute and sell its medical cannabis products on the Polish market.The approved Marketing Authorization Holder application is an important milestone and has meant 3 years of intensive work for the Company as it is required to proceed with the work to start selling the products on

    Announcement from the Annual General Meeting in ODI Pharma AB (publ)

    This is an unofficial translation of a notice to the Annual General Meeting in ODI Pharma AB (publ), originally drafted in Swedish. In case of any discrepancies between the Swedish original and this translation, the Swedish version shall prevail. Today, the 16[th] of December 2022, ODI Pharma AB (publ) held its Annual General Meeting (“AGM”). A summary of the resolutions follows below. The resolutions were made with the required majority.Adoption of the income statement and balance sheet The AGM resolved to adopt the profit and loss account and balance sheet presented, and the

    ODI Pharma AB publishes the annual report for the fiscal year 2021/2022

    The Board of Directors and the Chief Executive Officer of ODI Pharma AB (“ODI Pharma”) hereby publishes the annual report for the fiscal year 2021/2022. The annual report, along with the accompanying auditor’s report, is available as an attached file and on the websites of ODI Pharma (www.odipharma.com) and Spotlight Stock Market (www.spotlightstockmarket.com). A Swedish translation of the annual report is also available on www.odipharma.com.For more information on ODI Pharma, please contact: Derek Simmross, CEO, ODI Pharma AB E-mail: info@odipharma.com   ODI Pharma AB ODI

    ODI Pharma AB postpones publication of interim report and annual report until November 25, 2022

    ODI Pharma AB (“ODI” or the “Company”) stated in its year-end report that the interim report for the first quarter of 2022/2023 and the annual report for the fiscal year 2021/2022 would be published on November 24, 2022. Instead, the interim report and the annual report will be published on November 25, 2022, three weeks before the Annual General Meeting on December 16, 2022.For more information, please contact: Derek Simmross, CEO, ODI Pharma AB E-mail: info@odipharma.com   ODI Pharma AB ODI Pharma, based on its European network, subsidiaries and affiliates, is a producer and

    ODI Pharma AB: Publication of year-end report for the fiscal year 2021/2022

    ODI Pharma AB (“ODI” or the “Company”) hereby publishes its year-end report for the period July 2021 – June 2022. The report is available as an attached document to this press release and on the Company’s website (www.odipharma.com). Below is a summary of the report.Fourth quarter (2022-04-01 – 2022-06-30) The Group's net sales amounted to SEK 14,233 (0). The Group's loss after financial items amounted to SEK -2,378,022 (-1,886,158). Result per share amounted to SEK -0,16 (-0,12).* The solidity as of 2022-06-30 was 88,48% (96,55%).** Fiscal year (2021-07-01 – 2022-06-30)

    ODI Pharma AB: Publication of interim report Q3 2021/2022

    ODI Pharma AB (“ODI” or the “Company”) hereby publishes its interim report for the period July 2021 – March 2022. The report is available as an attached document to this press release and on the Company’s website (www.odipharma.com). Below is a summary of the report.Third quarter (2022-01-01 – 2022-03-31) The Group's net sales amounted to SEK 71,298 (0). The Group's loss after financial items amounted to SEK -2,344,281 (-41,280). Result per share amounted to SEK -0.15 (0).* The solidity as of 2022-03-31 was 95.11 % (99.63 %).** Nine months (2021-07-01 – 2022-03-31) The

    Correction: ODI Pharma AB: Publication of half-year report 2021

    Correction: ODI Pharma hereby discloses a revised half-year report for the period July – December 2021. In the previous report, the cost of goods sold was incorrect for the period and first six months, thereby impacting the operating profit and below in profit and loss. Further, the finished goods and goods for resale in the balance sheet has been adjusted. Also, other equity including result for the period is adjusted in the balance sheet. Finally, change in inventories and ongoing works is adjusted in the cash flow statement, thereby impacting the cash flow for the period. The revised half-

    ODI Pharma AB: Publication of half-year report 2021

    ODI Pharma AB (“ODI” or the “Company”) hereby publishes its half-year report for the period July – December 2021. The report is available as an attached document to this press release and on the Company’s website (www.odipharma.com). Below is a summary of the report.Second quarter (2021-10-01 – 2021-12-31) The Group's net sales amounted to SEK 458,620 (0). The Group's loss after financial items amounted to SEK -2,049,565 (-771,779). Result per share amounted to SEK -0.13 (-0.05).* The solidity as of 2021-12-31 was 93 % (98 %).** Six months (2021-07-01 – 2021-12-31) The

    ODI Pharma AB: Publication of interim report for the first quarter 2021/2022

    ODI Pharma AB (“ODI Pharma” or the “Company”) hereby publishes its interim report concerning the period July 2021 – September 2021. The report is available as an attached document to this press release and on the Company’s website (www.odipharma.com). Below is a summary of the report.First quarter (2021-07-01 – 2021-09-30) The Group's net sales amounted to SEK 0 (0). The Group's loss after financial items amounted to SEK -1,175,388 (-1,268,107). Result per share amounted to SEK -0.08 (-0.08).* The solidity as of 2021-09-30 was 94 % (97 %).** * The Company’s result per share:

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe